Up:

Boston Scientific Rises on Acquisition News +4.3%

Boston Scientific's stock saw a significant increase following the announcement of its definitive agreement to acquire Bolt Medical. Bolt Medical specializes in advanced laser platforms for intravascular lithotripsy, a technology that complements Boston Scientific's existing portfolio. The acquisition involves an initial payment of approximately $443 million for the 74% of Bolt Medical not already owned by Boston Scientific, with potential additional payments of up to $221 million based on regulatory milestones. The transaction is expected to be slightly dilutive to Boston Scientific's adjusted earnings per share in 2025, but the company anticipates offsetting this with internal cost savings.

Meta and eBay Collaboration Impacts Stock Prices +10.7%

Meta announced a test integration of eBay listings into its Facebook Marketplace, aiming to address competition concerns raised by the European Commission. This move is seen as a constructive response to a previous fine and regulatory demands. As a result, eBay's stock surged by over 10%, benefiting from increased exposure through Facebook's audience. Conversely, Meta's stock fell, possibly due to ongoing regulatory challenges and the implications of the integration.

ANSYS and Synopsys Await UK Approval for Takeover +1.6%

ANSYS and Synopsys are awaiting potential acceptance from the UK Competition and Markets Authority (CMA) for their proposed $35 billion takeover. The outcome of this regulatory review will be crucial for the progression of the acquisition, impacting both companies' strategic growth plans and market positions.

Arcadium Lithium Shares Rise on Rio Tinto Buyout Clearance +8.6%

Arcadium Lithium's shares increased after receiving clearance from the Committee on Foreign Investment in the U.S. for its acquisition by Rio Tinto. The merger, valued at $6.7 billion, has satisfied or waived merger control clearances in several countries, including the U.S. The transaction is still subject to approvals in Australia, Canada, and Italy, along with other customary conditions.

Cal-Maine Foods Sees Growth from Higher Egg Prices + 4.7%

Cal-Maine Foods reported a significant rise in its fiscal second-quarter results, driven by strong demand and higher egg prices. The company's net income surged to $4.47 per share, surpassing analyst expectations. Sales increased to $954.7 million, fueled by a rise in the net average selling price for shell eggs and an increase in total dozens sold. 

Down:

American International Group Downgraded by Goldman Sachs -3.4%

American International Group (AIG) experienced a shift in its stock rating as Goldman Sachs downgraded it from "Buy" to "Neutral," adjusting the price target from $83 to $79. Despite this downgrade, AIG maintains an average rating of "overweight" with a mean price target of $84.35 according to analysts polled by FactSet. This adjustment reflects a more cautious outlook on AIG's stock performance, potentially influencing investor sentiment.

Instacart and Ulta Beauty Partnership -3%

Following the announcement of its collaboration with Instacart for same-day delivery services across the US, Ulta's stock declined, possibly due to concerns about the impact on traditional retail sales or profit margins from the delivery service. This partnership allows Ulta Beauty products to be delivered from over 1,400 stores via Instacart, enhancing convenience for customers. 

UBS Adjusts Moderna's Price Target -7.1%

UBS revised its price target for Moderna, lowering it from $108 to $96 while maintaining a "Buy" rating. Despite this adjustment, Moderna holds an average rating of "hold" with a mean price target of $70.80 according to FactSet analysts. The revised target reflects UBS's updated expectations for Moderna's financial performance and market conditions.

IonQ Declines After Nvidia CEO's Remarks -42.7%

Quantum computing stocks, including Rigetti Computing, Quantum Computing, IonQ, and D-Wave Quantum, experienced significant declines following comments from Nvidia's CEO, Jensen Huang. He suggested that "very useful quantum computers" are likely two decades away, which may have dampened investor enthusiasm for the sector.